Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (CLOSURE-AF)

  • End date
    Mar 1, 2025
  • participants needed
  • sponsor
    Charite University, Berlin, Germany
Updated on 28 February 2022
vitamin k
vascular disease
left atrial appendage closure
anticoagulation therapy


The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).


The individualized therapy with oral anticoagulants is considered to be an essential preventive therapy in patients with atrial fibrillation. The risk of stroke can be reduced by approximately 65%. However, long-term anticoagulation therapy also increases the risk of major bleeding.

A significant proportion of patients at high risk of stroke do not tolerate long-term anticoagulation due to various relative or absolute contraindications. As demonstrated in previous studies with non-vitamin K antagonist anticoagulants (NOAK), 20-25% of patients were unable to tolerate long-term anticoagulation therapy.

For this reason, additional therapeutic approaches for stroke prevention in patients with atrial fibrillation have been developed.

A promising approach is catheter-based closure of the left atrial appendage, because more than 90% of cardiac thrombi in patients with non-valvular atrial fibrillation are detected in the left atrial appendage. Recent registry studies show that the safety of LAA occluder implantation is promising. However, further scientific studies are required, in order to explore more benefits of the underlying method and eligible patients for implantation.

Study objectives:

The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).

Condition Atrial Fibrillation
Treatment Clopidogrel, Rivaroxaban, Acetylsalicylic acid, Warfarin, Phenprocoumon, Apixaban, Dabigatran, Edoxaban, CE-mark approved LAA closure devices
Clinical Study IdentifierNCT03463317
SponsorCharite University, Berlin, Germany
Last Modified on28 February 2022


Yes No Not Sure

Inclusion Criteria

Signed written informed consent
Documented atrial fibrillation (paroxysmal, persistent, long-standing persistent or permanent)
CHA2DS2VASc-Score 2
High risk of bleeding under oral anticoagulation or contraindication for (N)OAC therapy, in particular patients with at least one of the following conditions (a-e)
HAS-BLED-Score 3
Prior intracranial/intraspinal bleed, intraocular bleed compromising vision (BARC: type 3c)
Hemorrhagic/bleeding complication fulfilling BARC type 3a or 3b: gastrointestinal tract, genitourinary tract or respiratory tract bleeding, where the patient is considered to be at a persistently increased risk of bleeding, e.g. the cause of bleeding cannot be successfully eliminated
Chronic kidney disease with eGFR 15-29 ml/min/1.73 m2
Any recurrent bleeding making chronic anticoagulation not feasible
Subject eligible for an LAA occluder device
Age 18 years
Willing and capable of providing informed consent, participating in all associated study activities

Exclusion Criteria

Absolute contraindication to acetylsalicylic acid
Comorbidities other than AF requiring chronic (N)OAC therapy, e.g. mechanical heart valve prosthesis
Symptomatic carotid disease (if not treated)
Complex aortic atheroma with mobile plaque (Kronzon classification grade V)
Heart transplant
Active infection or active endocarditis or other infections resulting in bacteremia
Cardiac tumor
Severe liver failure (Child-Pugh class C or liver failure with coagulopathy)
Severe renal failure (GFR <15 ml/min/1.73m2)
Pregnancy or breastfeeding
For female patients of reproductive potential: Unwilling to agree to use a highly effective method of contraception (Pearl index <1) throughout the study period
Subject with participation in another interventional clinical trial during this study or within 30 days before entry into this trial
Known terminating disease with life expectancy <1 year (including those with end-stage heart failure)
Subjects, who are committed to an institution due to binding official or court order
Subject who is dependent on the Site, the Site Investigator, any sub- investigator, his/her representative and/or the sponsor
Persons who are not proficient in the German language
Acute heart failure within the last 30 days
Cardiac intervention within the last 30 days
Subjects with planned cardiac or non-cardiac surgery or intervention. (These subject can be included 30 days after such intervention / surgery.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note